135 related articles for article (PubMed ID: 14996868)
1. Prostate cancer screening at National Cancer Institute comprehensive and clinical cancer centers.
Taylor KL; Africano NL; Schwartz M; Cullen J; Ahaghotu C
J Natl Cancer Inst; 2004 Mar; 96(5):414-5. PubMed ID: 14996868
[No Abstract] [Full Text] [Related]
2. Prostate cancer: numbers may not tell the whole story.
Reynolds T
J Natl Cancer Inst; 2000 Dec; 92(23):1873-6. PubMed ID: 11106674
[No Abstract] [Full Text] [Related]
3. Risks of PSA screening now better understood.
Peres J
J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
[No Abstract] [Full Text] [Related]
4. Uninformed compliance or informed choice? A needed shift in our approach to cancer screening.
Stefanek ME
J Natl Cancer Inst; 2011 Dec; 103(24):1821-6. PubMed ID: 22106094
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer: informing men about their options.
Mahon SM
Clin J Oncol Nurs; 2005 Oct; 9(5):625-7. PubMed ID: 16235590
[No Abstract] [Full Text] [Related]
6. Counseling Patients About Prostate Cancer Screening.
Stevermer JJ; Fink KS
Am Fam Physician; 2018 Oct; 98(8):478-483. PubMed ID: 30277734
[No Abstract] [Full Text] [Related]
7. The National Cancer Institute Multi-Screening Trial.
Prorok P
Can J Oncol; 1994 Nov; 4 Suppl 1():98-9; discussion 100-1. PubMed ID: 8853500
[No Abstract] [Full Text] [Related]
8. Balancing the benefits and risks of choice.
The Lancet
Lancet; 2016 Sep; 388(10050):1129. PubMed ID: 27650077
[No Abstract] [Full Text] [Related]
9. Editorial panel on informed consent for PSA screening.
Ramsden AR; Chodak G
Urology; 2003 Sep; 62(3):589. PubMed ID: 12946782
[No Abstract] [Full Text] [Related]
10. [Informed consent for patients on early recognition of prostate carcinoma is insufficient].
Börgermann C; vom Dorp F; Rossi R; Schenck M; Luboldt HJ; Rübben H
Urologe A; 2009 Sep; 48(9):997-8, 1000-1. PubMed ID: 19680621
[TBL] [Abstract][Full Text] [Related]
11. Informed consent for prostate-specific antigen screening.
Carter HB
Urology; 2003 Jan; 61(1):13-4. PubMed ID: 12559256
[No Abstract] [Full Text] [Related]
12. ACP issues guidelines on the early detection of prostate cancer and screening for prostate cancer.
Rose VL
Am Fam Physician; 1997 Oct; 56(6):1674-5. PubMed ID: 9351433
[No Abstract] [Full Text] [Related]
13. Lung cancer screening gets risk-specific.
Peres J
J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
[No Abstract] [Full Text] [Related]
14. Prostate cancer. Examining the risks and benefits of screening.
Cotter VT
Adv Nurse Pract; 1998 Jul; 6(7):51-3. PubMed ID: 9782799
[No Abstract] [Full Text] [Related]
15. Epidemiology and screening for prostate cancer.
Moul JW
Am J Manag Care; 1997 Aug; 3(8):1200-5; quiz 1208, 1210. PubMed ID: 10170302
[TBL] [Abstract][Full Text] [Related]
16. Simulated screening for prostate cancer: the useful model.
Church TR
J Natl Cancer Inst; 2003 Jun; 95(12):838-9. PubMed ID: 12813160
[No Abstract] [Full Text] [Related]
17. Do men know that they have had a prostate-specific antigen test? Accuracy of self-reports of testing at 2 sites.
Chan EC; Vernon SW; Ahn C; Greisinger A
Am J Public Health; 2004 Aug; 94(8):1336-8. PubMed ID: 15284039
[TBL] [Abstract][Full Text] [Related]
18. Counseling patients about prostate cancer screening.
Foxhall LE; Von Eschenbach AC
Am Fam Physician; 2002 May; 65(9):1752, 1754, 1757. PubMed ID: 12018801
[No Abstract] [Full Text] [Related]
19. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
20. Re: Is a screening interval of every 4 years for prostate cancer acceptable?
Braillon A
J Natl Cancer Inst; 2008 Feb; 100(3):222-3; author reply 223-4. PubMed ID: 18257153
[No Abstract] [Full Text] [Related]
[Next] [New Search]
